Document is current
Any future updates will be listed below
-
Authors
Santra, Mithun
Geary, Moira L.
Rubin, Elizabeth
Hsu, Michael Y. S.
Funderburgh, Martha L.
Chandran, Christine
Du, Yiqin
Dhaliwal, Deepinder K.
Jhanji, Vishal
Yam, Gary Hin-Fai http://orcid.org/0000-0002-8445-3669
-
Funding
Funding for this research was provided by:
Hillman Foundation
U.S. Department of Defense (W81XWH-19-1-0778)
Immune Transplant and Therapy Centre, UPMC
National Institutes of Health (RMIP U01-EY035252)
- License Information
-
More Information
Article History
Received: 13 July 2023
Accepted: 26 December 2023
First Online: 8 January 2024
Declarations
:
: The use of donor corneas followed the tenets of the Declaration of Helsinki and was approved by The University of Pittsburgh, Committee for Oversight of Research and Clinical Training Involving Decedents (CORID), Protocol #161 “Stem cells for Corneal Engineering & Regeneration” approved on May 9, 2023. Animal studies were conducted in strict accordance with the guidelines for the Care and Use of Laboratory Animals set forth by the NIH and The Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The study protocol was approved by the Institutional Animal Care and Use Committee (Protocol IS00018586 “Molecular Mechanism and Therapy for Corneal Scarring—Stem Cells for Corneal Engineering” approved on Feb 1, 2021) and the Human Stem Cell Research Oversight (hSCRO) (Protocol# ES-07-019-R “Corneal Stem Cell Therapy” approved on May 15, 2023), at the University of Pittsburgh.
: Not applicable.
: The authors declare that they have no competing interests.
